Pilot phase III immunotherapy study in early-stage breast cancer patients using oxidized mannan-MUC1 [ISRCTN71711835]

被引:135
作者
Apostolopoulos, Vasso [1 ]
Pietersz, Geoffrey A.
Tsibanis, Anastasios
Tsikkinis, Annivas
Drakaki, Heleni
Loveland, Bruce E.
Piddlesden, Sara J.
Plebanski, Magdalena
Pouniotis, Dodie S.
Alexis, Michael N.
McKenzie, Ian F.
Vassilaros, Stamatis
机构
[1] Burnet Inst Austin, Immunol & Vaccine Lab, Heidelberg, Vic, Australia
[2] Prolipsis Med Ctr, Athens, Greece
[3] Natl Hellen Res Fdn, Inst Biol Res & Biotechnol, Athens, Greece
基金
英国医学研究理事会;
关键词
D O I
10.1186/bcr1505
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Introduction Mucin 1 (MUC1) is a high molecular weight glycoprotein overexpressed on adenocarcinoma cells and is a target for immunotherapy protocols. To date, clinical trials against MUC1 have included advanced cancer patients. Herein, we report a trial using early stage breast cancer patients and injection of oxidized mannan-MUC1. Method In a randomized, double-blind study, 31 patients with stage II breast cancer and with no evidence of disease received subcutaneous injections of either placebo or oxidized mannan-MUC1, to immunize against MUC1 and prevent cancer reoccurrence/metastases. Twenty-eight patients received the full course of injections of either oxidized mannan-MUC1 or placebo. Survival and immunological assays were assessed. Results After more than 5.5 years had elapsed since the last patient began treatment (8.5 years from the start of treatment of the first patient), the recurrence rate in patients receiving the placebo was 27% (4/15; the expected rate of recurrence in stage II breast cancer); those receiving immunotherapy had no recurrences (0/16), and this finding was statistically significant ( P = 0.0292). Of the patients receiving oxidized mannan-MUC1, nine out of 13 had measurable antibodies to MUC1 and four out of 10 had MUC1-specific T cell responses; none of the placebo-treated patients exhibited an immune response to MUC1. Conclusion The results suggest that, in early breast cancer, MUC1 immunotherapy is beneficial, and that a larger phase III study should be undertaken.
引用
收藏
页数:11
相关论文
共 47 条
[1]   MUC1-specific immune responses in human MUC1 transgenic mice immunized with various human MUC1 vaccines [J].
Acres, B ;
Apostolopoulos, V ;
Balloul, JM ;
Wreschner, D ;
Xing, PX ;
Ali-Hadji, D ;
Bizouarne, N ;
Kieny, MP ;
McKenzie, IFC .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2000, 48 (10) :588-594
[2]  
Agrawal B, 1996, J IMMUNOL, V157, P2089
[3]  
Apostolopoulos V, 2000, METH MOL B, V125, P455
[4]  
Apostolopoulos V., 2001, Current Molecular Medicine (Hilversum), V1, P469, DOI 10.2174/1566524013363645
[5]  
Apostolopoulos V, 1999, CURR OPIN MOL THER, V1, P98
[6]   A glycopeptide in complex with MHC class I uses the GaINAc residue as an anchor [J].
Apostolopoulos, V ;
Yuriev, E ;
Ramsland, PA ;
Halton, J ;
Osinski, C ;
Li, WJ ;
Plebanski, M ;
Paulsen, H ;
McKenzie, IFC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (25) :15029-15034
[7]  
APOSTOLOPOULOS V, 1994, CANCER RES, V54, P5186
[8]   Crystal structure of a non-canonical low-affinity peptide complexed with MHC class I: A new approach for vaccine design [J].
Apostolopoulos, V ;
Yu, MM ;
Corper, AL ;
Teyton, L ;
Pietersz, GA ;
McKenzie, IFC ;
Wilson, IA .
JOURNAL OF MOLECULAR BIOLOGY, 2002, 318 (05) :1293-1305
[9]   PRODUCTION OF ANTI-BREAST CANCER MONOCLONAL-ANTIBODIES USING A GLUTATHIONE-S-TRANSFERASE-MUC1 BACTERIAL FUSION PROTEIN [J].
APOSTOLOPOULOS, V ;
XING, PX ;
TRAPANI, JA ;
MCKENZIE, IFC .
BRITISH JOURNAL OF CANCER, 1993, 67 (04) :713-720
[10]   Cell-mediated immune responses to MUC1 fusion protein coupled to mannan [J].
Apostolopoulos, V ;
Pietersz, GA ;
McKenzie, IFC .
VACCINE, 1996, 14 (09) :930-938